Pharma BD Deal Intelligence

Lupin Limited / Gavis Pharmaceuticals LLC and Novel Laboratories, Inc.

2015 · Acquisition/Merger · $880M · Complete

Announcement Sentiment

Strongly positive

Lupin agreed to acquire US generics maker Gavis Pharmaceuticals and Novel Laboratories for $880M, the largest US acquisition by an Indian pharma at the time. Provided Lupin its first US manufacturing facility (New Jersey) and broadened pipeline in dermatology and controlled substances.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Jul 23, 2015
Closed Mar 21, 2016
Deal value $880M
Deal type Acquisition/Merger
Therapeutic area Multiple (generics, dermatology, controlled substances)
Indications Multiple (generics, dermatology, controlled substances)
Key assets US generics portfolio (66 ANDAs pending; 65+ pipeline products)
Mechanism Generic small molecules

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals